International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (393-398), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Diagnosis and roles of Treatment for Graves' disease: Systematic review

[1]Abdullah hamed algethami, [2]Abdulateef ibrahim alsulaimany,
[3]Turki Sulaiman Alghuraybi, [4]Faisal Abdullah Habib, [5]Ibrahim Abdulaziz Turki

Abstract: **Graves' disease (GD) is an autoimmune disease brought on by thyroid-receptor antibodies that trigger the thyrotrophin receptor, causing stimulation of cyclic adenosine monophosphate synthesis and production of thyroid hormonal agents in the follicular cells. The aim of this review is to show the current approach to diagnosis and therapy of Graves' disease, particularly putting the particular emphasis on paying attention to the methods used in nuclear medicine. Systematic review of the literature was performed to examine contemporary literature up to October 2016 evaluating the diagnosis and management approaches of GD. Studies were identified by two methods: 1) PubMed search using (''graves' disease'' [MeSH Major Topic] and ''diagnosis and treatment''[MeSH Terms] OR ''graves' disease''[MeSH Major Topic] and ''thyroidectomy managment''[MeSH Terms]); and 2) a manual review of the bibliographies of each article obtained from the PubMed search. GD is a typical condition whose management typically presents complicated obstacles. A 12-18-month course of thionamide treatment is normally first-line treatment in Australia and the UK, with regression treated with RAI or overall thryoidectomy.**

Keywords: **Graves' disease, thyroidectomy.**

1. INTRODUCTION

Graves' disease (GD) is an autoimmune disease brought on by thyroid-receptor antibodies that trigger the thyrotrophin receptor, causing stimulation of cyclic adenosine monophosphate synthesis and production of thyroid hormonal agents in the follicular cells [(1,2)]. Presently the occurrence of GD is 0.5 % of the population and is the underlying etiology for 50--80 % of cases of hyperthyroidism [(3)]. GD is not just connected with a decline in lifestyle, however if left neglected, it can result in heart disease, consisting of atrial fibrillation, cardiomyopathy, and heart disease [(4,5)]. Environmental and hereditary elements (80%: 20%) are accountable for the increase of the disease. Ecological elements consist of: smoking cigarettes, tension, pregnancy, sex hormonal agents, infections and sufficient usage of iodine [(6,7,8)]. The immunopathogenesis of Graves' disease is complex. Antibodies versus the TSH receptor (TRAb) are accountable for hyperthyroidism (TRAB) [(8,9)]. These antibodies, on the surface area of thyroid cells, relate to TSH receptors, triggering constant and unchecked stimulation of the thyroid, resulting in extreme synthesis of the thyroid hormonal agents: thyroxine (T4) and triiodothyronine (T3) and its hypertrophy. The spontaneous remission of the disease takes place in 30% of patients [(8)]. Nuclear medication permits carrying out both diagnosis and treatment of Graves' disease. Making use of antithyroid drugs as the first-line treatment differs in various areas of the world. In the United States, antithyroid drugs are frequently utilized as an accessory prior to radioactive iodine or surgery as an outcome of the high regression rate with antithyroid drugs as primary treatment. The regression normally takes place within the very first 3 to 6 months after medication is stopped [(1)].

The varied symptoms of the condition period beyond its regional results on the thyroid, showing its systemic autoimmune and sympathomimetic symptoms. The occurrence of specific elements of Graves' disease and supporting images are shown in **Table 1** [**(9,10)**] .

Table1: Components of Graves' disease: prevalence.

Feature	Prevalence (%)
Hyperthyroidism and diffuse goitre	95%
Thyroid eye disease [a]	50%
Pretibial myxoedema	5%
Acropachy	1%
Thyroid eye disease without hyperthyroidism [‘Euthyroid Graves’ disease']	5%

Percentages are based on a cohort of patients seen by the senior author [9].
[a]As defined by the NO-SPECS classification [10].

The aim of this review is to show the current approach to diagnosis and therapy of Graves’ disease, particularly putting the particular emphasis on paying attention to the methods used in nuclear medicine, which may be useful to GP doctors and specialists providing care for patients with Graves’ disease.

Methodology:

Systematic review of the literature was performed to examine contemporary literature up to October 2016 evaluating the diagnosis and management approaches of GD . Studies were identified by two methods: 1) PubMed search using (‘‘graves’ disease’’ [MeSH Major Topic] and ‘‘diagnosis and treatment’’[MeSH Terms] OR ‘‘graves’ disease’’[MeSH Major Topic] and ‘‘thyroidectomy managment’’[MeSH Terms]); and 2) a manual review of the bibliographies of each article obtained from the PubMed search. All identified studies were examined independently by all Authors

2. RESULTS AND DISCUSSION

Diagnosis of Graves disease:

The clinical signs and symptoms of Graves's disease are shared by other types of thyrotoxicosis [11]. Tomb disease is associated with distinct extrathyroidal symptoms, consisting of orbital disease (Graves ophthalmopathy) [12,13,14] skin modifications (thyroid dermopathy) and, seldom, fingertip and nail problems (thyroid acropachy) **(Figure1)** [15]. When these particular signs happen in combination with hyperthyroidism and scattered goitre, diagnosis of Graves's disease is simple. In patients without apparent hyperthyroidism or ocular indications, and missing or nodular goitre, Graves’s disease requires to be distinguished from other possible causes of hyperthyroidism, such as hazardous adenoma or hazardous multinodular goitre. Graves's disease is especially challenging to detect in senior patients, in whom hyperthyroidism is typically connected with couple of signs and indications [16], and in unusual patients with Graves ophthalmopathy who do not have hyperthyroidism (so-called euthyroid Graves’s disease or euthyroid ophthalmic disease) [17].



Figure1: Images of extrathyroidal features of Graves' disease: characteristic features of thyroid eye disease including marked chemosis and eyelid oedema (A); eyelid retraction, swelling and exophthalmos (B). Also shown are features of thyroid acropachy in a patient with Graves' disease including soft-tissue oedema and clubbing (C) with the characteristic eroded bone margins of the phalanges suggestive of new periosteal bone formation and periosteitis (D). [9,10]

Laboratory test s as a procedure for diagnosis of GD:

In 2011, a big global questionnaire-based study [18] was performed to examine the management of Graves's disease amongst members of the Endocrine Society, the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) [18]. The majority of participants were from North America (63%), and the rest were from Europe (12.9%), South America (11.3%), Asia and Oceania (9.5%) or the Middle East and Africa (3.4%) [18]. If hyperthyroidism is believed, this study revealed that measurement of serum levels of TSH and totally free T4 are concomitantly asked for by 90% of endocrinologists. One research study [19] revealed a technique remains in line with the ATA and AACE standards on diagnosis of hyperthyroidism; therefore, the finding of increased levels of complimentary T4 and reduced levels of TSH is generally adequate to verify the diagnosis of Graves's disease. Serum levels of complimentary T3 or overall T3 are likewise frequently increased in patients with hyperthyroidism, however measurement of complimentary T3 or overall T3 levels was just asked for by 40% of the endocrinologists in the above study (without any geographical distinctions in whether this extra test was asked for) (18). However, 2-4% of patients with hyperthyroidism have regular serum levels of complimentary T4 and increased serum levels of complimentary T3 or overall T3 (so-called T3 thyrotoxicosis) [11]. Therefore, in the preliminary evaluation of thyroid status in a patient with thought hyperthyroidism, concomitant decision of the serum levels of complimentary T4, totally free T3 (or overall T3) and TSH is recommended [11].

Management of Graves disease

The ideal treatment for Graves disease should restore normal thyroid function, avoid recurrence of hyperthyroidism, prevent development of hypothyroidism and prevent de novo occurrence or progression of Graves ophthalmopathy.

Treatment GD with antithyroid drugs:

As two identified studies [21,22] stated that the thionamide-derived antithyroid drugs authorized for usage in patients with Graves's disease consist of methimazole, carbimazole (which after absorption is transformed into the active type methimazole) and propylthiouracil. These drugs can have either indirect or direct (through normalization of thyroid status) immunosuppressive impacts,[21,22] however their primary mode of action is to reduce excess thyroid hormonal agent synthesis by hindering TPO, therefore minimizing the production of T3 and T4. Antithyroid drugs, such as potassium perchlorate for amiodarone-induced thyrotoxicosis, which are not thionamide-based, have actually restricted applications [22,23]. The present ATA and AACE standards suggest that methimazole ought to be utilized in all patients chosen for treatment with antithyroid drugs, other than females throughout their very first trimester of pregnancy [19]. Propylthiouracil is still the recommended treatment choice for pregnant females, owing to the danger of embryopathy related to carbimazole and methimazole [24,25,26]. Propylthiouracil was for several years the first-choice antithyroid drug in both the USA and South America [27]. However, propylthiouracyl can trigger extreme hepatotoxic impacts, which may be deadly or need liver hair transplant [28,29,30]. Methimazole is utilized in the majority of European nations and Japan, whereas carbimazole is primarily utilized in the UK. A research study released in 2010 revealed that throughout 1991-2008 the yearly prescriptions of methimazole in the USA increased by ninefold, and this representative has actually been the most frequently recommended antithyroid drug in this area considering that 1996 [27].

^{131}I-radiotherapy for treatment of GD:

^{131}I is an effective therapy for patients with Graves's disease; we have included a study [31] showed that as it causes gradual necrosis of thyroid cells. The loss of practical thyroid tissue ultimately leads to hypothyroidism in many patients who get this treatment [32]. Indeed, hypothyroidism is a wanted objective of ^{131}I-radiotherapy since making use of low dosages of this isotope, focused on bring back euthyroidism, is related to a high rate of reoccurrence of hyperthyroidism [19]. ^{131}I-radiotherapy can be administered in repaired quantities or as calculated dosages based upon the approximated size of the thyroid and uptake of ^{131}I 24 h after administration, as determined by thyroid scintigraphy [31]. No agreement has actually yet been reached on whether repaired dosages or computed dosages need to be used. Among the arguments supporting using set dosages is that this technique needs neither an extra center check out nor regional knowledge in making use of thyroid scintigraphy to determine ^{131}I uptake [4]. A study of UK professionals revealed that repaired dosages were utilized by 70% of participants [32]. Use of high dosages ($\geq$ 0.78 GBq) of ^{131}I is related to a greater treatment success rate and earlier accomplishment of remedy than are low dosages of ^{131}I ($\leq$ 0.56 GBq) [33]. The practice suggestions released by the ATA in 2011 [34]ought to be thoroughly followed to keep radiation security for the patient's close household after ^{131}I-radiotherapy.

Thyroidectomy for treatment of GD:

We included 6 studies [35,36,37,38,39,40] that have showed the surgery as a valid and definitive treatment for Graves's disease [35,36,37,38,39] but is used less frequently than ^{131}I-radiotherapy. Patient choices have a significant function in the option of surgery or ^{131}I-radiotherapy [40]. Thyroidectomy is plainly suggested in patients with regression of hyperthyroidism after antithyroid drug treatment and in those with big goitres, or when associated malignancy. In extraordinary situations, such as in pregnant females who cannot endure antithyroid drugs, thyroidectomy may be carried out throughout the 2nd trimester. Thyroidectomy may likewise be used to patients who decline 131I-radiotherapy, which is a typical event in some Asian nations. In chosen patients, such as those with small goiter or no suspicion of malignancy, minimally intrusive video-assisted thyroidectomy,[41] endoscopic subtotal thyroidectomy by the breast[42] or robot-assisted transaxillary thyroidectomy[43] may represent legitimate surgical techniques. The rates of issues of thyroid surgery, consisting of hypoparathyroidism, palsy of the reoccurring laryngeal nerve and injury infections, are inversely associated with cosmetic surgeon experience and yearly volume of thyroidectomies [44]. Total or near-total thyroidectomy is the favored treatment,[19] since subtotal thyroidectomy bears an increased threat of regression of hyperthyroidism [35,36]. Moreover, near-total or overall thyroidectomy does not increase the problem rate and has no negative impact on postoperative lifestyle, compared to subtotal thyroidectomy based upon the brief kind 36 survey [37]. An organized evaluation likewise revealed that surgery is more effective than ^{131}I-radiotherapy as conclusive treatment for Graves's disease, which overall thyroidectomy must be the favored surgical method [39]. A cost-effectiveness analysis of treatment alternatives for Graves's disease in the USA revealed that overall thyroidectomy is more economical than either long-lasting treatment with antithyroid drugs or ^{131}I-radiotherapy, for patients who are not in remission after an 18-month course of antithyroid drugs [38].

3. CONCLUSION

GD is a typical condition whose management typically presents complicated obstacles. A 12-18-month course of thionamide treatment is normally first-line treatment in Australia and the UK, with regression treated with RAI or overall thryoidectomy. Current advances in Graves' disease consist of increasing characterization of extrathyroidal organ participation, the emerging function of thyroid ultrasonography in the examination of Graves' disease and the introduction of unique small-molecule TSH-receptor ligands as prospective targets in the treatment of Graves' disease.the essential function in tracking and diagnosis of Graves'disease plays the level of hormonal agents of complimentary thyroxine and triiodothyronine.

Handy is an ultrasound of the thyroid scintigraphy which, due to its practical character, is an important enhance morphological research study and plays an essential function in the diagnosisand treatment in patients with Graves' disease. Due to its low expense and much higher level of sensitivity to determine the concentrations of antibodies versus the TSH receptor, this test must be carried out in every patient presumed of having Graves' disease, particularly in the lack of beyond thyroid signs consisting of Graves'ophthalmopathy.

REFERENCES

[1] Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003;24:802–35.

[2] Hegedu¨s L. Treatment of Graves' hyperthyroidism: evidencebased and emerging modalities. Endocrinol Metab Clin North Am. 2009;38:355–71.

[3] Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008;358:2594–605.

[4] Abraham-Nordling M, Wallin G, Tra¨isk F, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol. 2010;163:651–7.

[5] Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501–9.

[6] Brand OJ, Gough SCL. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol 2010; 322: 135–143.

[7] Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. Immunol Res 2012; 54: 191–203.

[8] Bartalena L, Diagnosis and management of Graves' disease: a global overview. Nat Rev Endocrinol 2013; 9: 724–734.

[9] El-Kaissi S., Frauman A.G., Wall J.R. (2004) Thyroid-associated ophthalmopathy: A practical guide to classification, natural history and management. Intern Med J 34: 482–491.

[10] Van Dyk H.J. (1981) Orbital Graves' disease. A modification of the "NO SPECS" classification. Ophthalmology 88: 479–483.

[11] Franklyn, J. A. & Boelaert, K. Thyrotoxicosis. Lancet 379, 1155–1166 (2012).

[12] Bartalena, L. & Tanda, M. L. Clinical practice. Graves' ophthalmopathy. N. Engl. J. Med. 360, 994–1001 (2009).

[13] Tanda, M. L. et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J. Clin. Endocrinol. Metab. 98, 1443–1449 (2013).

[14] Piantanida, E., Tanda, M. L., Lai, A., Sassi, L. & Bartalena, L. Prevalence and natural history of Graves' orbitopathy in the XXI century. J. Endocrinol. Invest. 36, 444–449 (2013).

[15] Fatourechi, V. Thyroid dermopathy and acropachy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 553–565 (2012).

[16] Boelaert, K., Torlinska, B., Holder, R. L. & Frannklyn, J. A. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J. Clin. Endocrinol. Metab. 95, 2715–2726 (2010).

[17] Bartalena, L., Pinchera, A. & Marcocci, C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr. Rev. 21, 168–199 (2000).

[18] Burch, H. B., Burman, K. D. & Cooper, D. S. A 2011 survey of clinical practice patterns in the management of Graves' disease. J. Clin. Endocrinol. Metab. 97, 4549–4558 (2012).

[19] Bahn, R. S. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21, 593–646 (2011).

[20] Yoshimura Noh, J. et al. Evaluation of a new rapid and fully automated electroluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid 18, 1157–1164 (2008).

[21] Weetman, A. P. How antithyroid drugs work in Graves' disease. Clin. Endocrinol. (Oxf.) 37, 317–318 (1992).

[22] Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905–917 (2005).

[23] Bogazzi, F., Tomisti, L., Bartalena, L., Aghini-Lombardi, F. & Martino, E. Amiodarone and the thyroid: a 2012 update. J. Endocrinol. Invest. 35, 340–348 (2012).

[24] Karlsson, F. A., Axelsson, O. & Melhus, H. Severe embriopathy and exposure to methimazole in early pregnancy. J. Clin. Endocrinol. Metab. 87, 947–948 (2001).

[25] Foulds, N., Walpole, I., Elmslie, F. & Mansour, S. Carbimazole embryopathy: an emerging phenotype. Am. J. Med. Genet. A 132A, 130–135 (2005).

[26] Clementi, M. et al. Treatment of hyperthyroidism in pregnancy and birth defects. J. Clin. Endocrinol. Metab. 95, E337–E341 (2010).

[27] Emiliano, A. B., Governale, L., Parks, M. & Cooper, D. S. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J. Clin. Endocrinol. Metab. 95, 2227–2233 (2010).

[28] Ruiz, J. K. et al. Fulminant hepatic failure associated with propylthiouracil. Ann. Pharmacother. 37, 224–228 (2003).

[29] Bahn, R. S. et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19, 673–674 (2009).

[30] Cooper, D. S. & Rivkees, S. A. Putting propylthiouracil in perspective. J. Clin. Endocrinol. Metab. 94, 1881–1882 (2009).

[31] Ross, D. S. Radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 364, 542–550 (2011).

[32] Vaidya, B., Williams, G. R., Abraham, P. & Pearce, S. H. S. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin. Endocrinol. (Oxf.) 68, 814–820 (2008).

[33] Sztal-Mazer, S. et al. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses. Thyroid 22, 991–995 (2012).

[34] Sisson, J. C. et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 21, 335–346 (2011).

[35] Palit, T. K., Miller, C. C. 3rd & Miltenburg, D. M. The efficacy of thyroidectomy for Graves' disease: a meta-analysis. J. Surg. Res. 90, 161–165 (2000).

[36] Annerbo, M., Stålberg, P. & Hellman, P. Management of Graves' disease is improved by total thyroidectomy. World J. Surg. 36, 1943–1946 (2012).

[37] Al-Adhami, A., Craig, W. & Krukowski, Z. H. Quality of life after surgery for Graves' disease: comparison of those having surgery intended to preserve thyroid function with those having ablative surgery. Thyroid 22, 494–500 (2012).

[38] In, H. et al. Treatment options for Graves disease: a cost-effectiveness analysis. J. Am. Coll. Surg. 209, 170–179 (2009).

[39] Genovese, B. M., Noureldine, S. I., Gleeson, E. M., Tufano, R. P. & Kandil, E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann. Surg. Oncol. 20, 660–667 (2013).

[40] Grodski, S., Stålberg, P., Robinson, B. G. & Delbridge, L. W. Surgery versus radioiodine therapy as definitive management for Graves' disease: the role of patient preference. Thyroid 17, 157–160 (2007).

[41] Miccoli, P. et al. Minimally invasive videoassisted thyroidectomy for benign thyroid disease: an evidence-based review. World J. Surg. 32, 1333–1340 (2008).

[42] Sasaki, A. et al. Endoscopic thyroidectomy by the breast approach: a single institution's 9-year experience. World J. Surg. 32, 381–385 (2008).

[43] Lee, J. & Chung, W. Y. Robotic surgery for thyroid disease. Eur. Thyroid J. 2, 93–101 (2013).

[44] Sosa, J. A., Mehta, P. J., Wang, T. S., Boudourakis, L. & Roman, S. A. A populationbased study of outcomes from thyroidectomy in aging Americans: at what cost? J. Am. Coll. Surg. 206, 1097–1105 (2008)